Sign up to save your podcasts
Or
Share Aspirin Elimination Cuts LVAD Bleeding Risk 11/20/25
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Aspirin Elimination Cuts LVAD Bleeding Risk 11/20/25
Welcome to Cardiology Today – Recorded November 20, 2025. This episode summarizes 5 key cardiology studies on topics like angiography and heart failure hospitalization. Key takeaway: Aspirin Elimination Cuts LVAD Bleeding Risk.
Article Links:
Article 1: Cardiac endogenous transmitter system: molecular features, functions, and clinical implications. (European heart journal)
Article 2: Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial. (European heart journal)
Article 3: Phase I Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial. (JACC. Heart failure)
Article 4: Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial. (JACC. Heart failure)
Article 5: Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes. (JACC. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/aspirin-elimination-cuts-lvad-bleeding-risk-11-20-25/
Featured Articles
Article 1: Cardiac endogenous transmitter system: molecular features, functions, and clinical implications.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41259103
Summary: Recent studies have identified several endogenous transmitter systems within cardiomyocytes and cardiac pacemaker cells, overturning the traditional belief that the heart lacked its own intrinsic signaling networks. These systems represent molecular networks that facilitate signal transmission directly within cardiac tissues. This discovery reveals that the heart possesses its own distinct intrinsic networks for transmitting signals. The findings provide novel insights into cardiac physiology and potential targets for therapeutic interventions.
Article 2: Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41259082
Summary: The OCCUPI trial investigated the impact of optical coherence tomography guidance compared to angiography guidance in patients with complex coronary lesions. This study classified patients who underwent optical coherence tomography-guided percutaneous coronary intervention into two groups based on meeting specific optimization criteria. This classification system enabled the detailed evaluation of the incidence, determinants, and clinical impact of stent optimization. The trial established a structured approach for assessing optimal stent placement using advanced imaging techniques.
Article 3: Phase I Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41258851
Summary: Patients with hypoplastic left heart syndrome frequently experience severe right ventricle dysfunction, often leading to shortened lifespans. Neonatal cardiac progenitor cells previously demonstrated improved right ventricle performance in animal models of pressure-overload induced dysfunction. The C. H. I. L. D. trial, a phase one randomized study, specifically applied this therapeutic strategy to patients with hypoplastic left heart syndrome. This trial represents a key step in evaluating autologous neonatal cardiac progenitor cells for enhancing right ventricle function in this vulnerable pediatric group.
Article 4: Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41258850
Summary: The Antiplatelet Removal and Hemocompatibility Events With the HeartMate three Pump trial demonstrated both safety and decreased bleeding by eliminating aspirin from the antithrombotic regimen for patients implanted with a HeartMate three left ventricular assist device. This finding established a crucial clinical protocol for reducing adverse events in these patients. This specific trial analysis further investigated associations between various pharmacologic therapies and hemocompatibility outcomes following left ventricular assist device implantation.
Article 5: Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41258849
Summary: The clinical presentation of heart failure with preserved ejection fraction varies across the spectrum of body mass index. This study established the relationship between body mass index and specific echocardiographic and hemodynamic characteristics in these patients. It also defined the association between body mass index and clinical outcomes, including heart failure hospitalization and death. This analysis utilized a large multicenter registry of patients diagnosed with heart failure with preserved ejection fraction.
Transcript
Today’s date is November 20, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Cardiac endogenous transmitter system: molecular features, functions, and clinical implications. Recent studies have identified several endogenous transmitter systems within cardiomyocytes and cardiac pacemaker cells, overturning the traditional belief that the heart lacked its own intrinsic signaling networks. These systems represent molecular networks that facilitate signal transmission directly within cardiac tissues. This discovery reveals that the heart possesses its own distinct intrinsic networks for transmitting signals. The findings provide novel insights into cardiac physiology and potential targets for therapeutic interventions.
Article number two. Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial. The OCCUPI trial investigated the impact of optical coherence tomography guidance compared to angiography guidance in patients with complex coronary lesions. This study classified patients who underwent optical coherence tomography-guided percutaneous coronary intervention into two groups based on meeting specific optimization criteria. This classification system enabled the detailed evaluation of the incidence, determinants, and clinical impact of stent optimization. The trial established a structured approach for assessing optimal stent placement using advanced imaging techniques.
Article number three. Phase one Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial. Patients with hypoplastic left heart syndrome frequently experience severe right ventricle dysfunction, often leading to shortened lifespans. Neonatal cardiac progenitor cells previously demonstrated improved right ventricle performance in animal models of pressure-overload induced dysfunction. The C. H. I. L. D. trial, a phase one randomized study, specifically applied this therapeutic strategy to patients with hypoplastic left heart syndrome. This trial represents a key step in evaluating autologous neonatal cardiac progenitor cells for enhancing right ventricle function in this vulnerable pediatric group.
Article number four. Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial. The Antiplatelet Removal and Hemocompatibility Events With the HeartMate three Pump trial demonstrated both safety and decreased bleeding by eliminating aspirin from the antithrombotic regimen for patients implanted with a HeartMate three left ventricular assist device. This finding established a crucial clinical protocol for reducing adverse events in these patients. This specific trial analysis further investigated associations between various pharmacologic therapies and hemocompatibility outcomes following left ventricular assist device implantation.
Article number five. Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes. The clinical presentation of heart failure with preserved ejection fraction varies across the spectrum of body mass index. This study established the relationship between body mass index and specific echocardiographic and hemodynamic characteristics in these patients. It also defined the association between body mass index and clinical outcomes, including heart failure hospitalization and death. This analysis utilized a large multicenter registry of patients diagnosed with heart failure with preserved ejection fraction.
Thank you for listening. Don’t forget to subscribe.
Keywords
angiography, heart failure hospitalization, coronary lesions, stem cell therapy, cardiac endogenous transmitter systems, neonatal cardiac progenitor cells, pediatric cardiology, right ventricle dysfunction, optical coherence tomography, signal transmission, echocardiography, pacemaker cells, heart failure with preserved ejection fraction, hemodynamics, stent optimization, body mass index, left ventricular assist device, cardiomyocytes, bleeding, hypoplastic left heart syndrome, cardiac physiology, aspirin, antithrombotic regimen, hemocompatibility-related adverse events, percutaneous coronary intervention.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • Follow
The post Aspirin Elimination Cuts LVAD Bleeding Risk 11/20/25 first appeared on Cardiology Today.
View all episodes
By Deconstructed CardiologyWelcome to Cardiology Today – Recorded November 20, 2025. This episode summarizes 5 key cardiology studies on topics like angiography and heart failure hospitalization. Key takeaway: Aspirin Elimination Cuts LVAD Bleeding Risk.
Article Links:
Article 1: Cardiac endogenous transmitter system: molecular features, functions, and clinical implications. (European heart journal)
Article 2: Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial. (European heart journal)
Article 3: Phase I Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial. (JACC. Heart failure)
Article 4: Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial. (JACC. Heart failure)
Article 5: Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes. (JACC. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/aspirin-elimination-cuts-lvad-bleeding-risk-11-20-25/
Featured Articles
Article 1: Cardiac endogenous transmitter system: molecular features, functions, and clinical implications.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41259103
Summary: Recent studies have identified several endogenous transmitter systems within cardiomyocytes and cardiac pacemaker cells, overturning the traditional belief that the heart lacked its own intrinsic signaling networks. These systems represent molecular networks that facilitate signal transmission directly within cardiac tissues. This discovery reveals that the heart possesses its own distinct intrinsic networks for transmitting signals. The findings provide novel insights into cardiac physiology and potential targets for therapeutic interventions.
Article 2: Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41259082
Summary: The OCCUPI trial investigated the impact of optical coherence tomography guidance compared to angiography guidance in patients with complex coronary lesions. This study classified patients who underwent optical coherence tomography-guided percutaneous coronary intervention into two groups based on meeting specific optimization criteria. This classification system enabled the detailed evaluation of the incidence, determinants, and clinical impact of stent optimization. The trial established a structured approach for assessing optimal stent placement using advanced imaging techniques.
Article 3: Phase I Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41258851
Summary: Patients with hypoplastic left heart syndrome frequently experience severe right ventricle dysfunction, often leading to shortened lifespans. Neonatal cardiac progenitor cells previously demonstrated improved right ventricle performance in animal models of pressure-overload induced dysfunction. The C. H. I. L. D. trial, a phase one randomized study, specifically applied this therapeutic strategy to patients with hypoplastic left heart syndrome. This trial represents a key step in evaluating autologous neonatal cardiac progenitor cells for enhancing right ventricle function in this vulnerable pediatric group.
Article 4: Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41258850
Summary: The Antiplatelet Removal and Hemocompatibility Events With the HeartMate three Pump trial demonstrated both safety and decreased bleeding by eliminating aspirin from the antithrombotic regimen for patients implanted with a HeartMate three left ventricular assist device. This finding established a crucial clinical protocol for reducing adverse events in these patients. This specific trial analysis further investigated associations between various pharmacologic therapies and hemocompatibility outcomes following left ventricular assist device implantation.
Article 5: Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41258849
Summary: The clinical presentation of heart failure with preserved ejection fraction varies across the spectrum of body mass index. This study established the relationship between body mass index and specific echocardiographic and hemodynamic characteristics in these patients. It also defined the association between body mass index and clinical outcomes, including heart failure hospitalization and death. This analysis utilized a large multicenter registry of patients diagnosed with heart failure with preserved ejection fraction.
Transcript
Today’s date is November 20, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Cardiac endogenous transmitter system: molecular features, functions, and clinical implications. Recent studies have identified several endogenous transmitter systems within cardiomyocytes and cardiac pacemaker cells, overturning the traditional belief that the heart lacked its own intrinsic signaling networks. These systems represent molecular networks that facilitate signal transmission directly within cardiac tissues. This discovery reveals that the heart possesses its own distinct intrinsic networks for transmitting signals. The findings provide novel insights into cardiac physiology and potential targets for therapeutic interventions.
Article number two. Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial. The OCCUPI trial investigated the impact of optical coherence tomography guidance compared to angiography guidance in patients with complex coronary lesions. This study classified patients who underwent optical coherence tomography-guided percutaneous coronary intervention into two groups based on meeting specific optimization criteria. This classification system enabled the detailed evaluation of the incidence, determinants, and clinical impact of stent optimization. The trial established a structured approach for assessing optimal stent placement using advanced imaging techniques.
Article number three. Phase one Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial. Patients with hypoplastic left heart syndrome frequently experience severe right ventricle dysfunction, often leading to shortened lifespans. Neonatal cardiac progenitor cells previously demonstrated improved right ventricle performance in animal models of pressure-overload induced dysfunction. The C. H. I. L. D. trial, a phase one randomized study, specifically applied this therapeutic strategy to patients with hypoplastic left heart syndrome. This trial represents a key step in evaluating autologous neonatal cardiac progenitor cells for enhancing right ventricle function in this vulnerable pediatric group.
Article number four. Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial. The Antiplatelet Removal and Hemocompatibility Events With the HeartMate three Pump trial demonstrated both safety and decreased bleeding by eliminating aspirin from the antithrombotic regimen for patients implanted with a HeartMate three left ventricular assist device. This finding established a crucial clinical protocol for reducing adverse events in these patients. This specific trial analysis further investigated associations between various pharmacologic therapies and hemocompatibility outcomes following left ventricular assist device implantation.
Article number five. Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes. The clinical presentation of heart failure with preserved ejection fraction varies across the spectrum of body mass index. This study established the relationship between body mass index and specific echocardiographic and hemodynamic characteristics in these patients. It also defined the association between body mass index and clinical outcomes, including heart failure hospitalization and death. This analysis utilized a large multicenter registry of patients diagnosed with heart failure with preserved ejection fraction.
Thank you for listening. Don’t forget to subscribe.
Keywords
angiography, heart failure hospitalization, coronary lesions, stem cell therapy, cardiac endogenous transmitter systems, neonatal cardiac progenitor cells, pediatric cardiology, right ventricle dysfunction, optical coherence tomography, signal transmission, echocardiography, pacemaker cells, heart failure with preserved ejection fraction, hemodynamics, stent optimization, body mass index, left ventricular assist device, cardiomyocytes, bleeding, hypoplastic left heart syndrome, cardiac physiology, aspirin, antithrombotic regimen, hemocompatibility-related adverse events, percutaneous coronary intervention.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • Follow
The post Aspirin Elimination Cuts LVAD Bleeding Risk 11/20/25 first appeared on Cardiology Today.